VEREGEN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968973 | ANI PHARMS | Method for treating hyperplasia |
Apr, 2017
(7 years ago) | |
| US5795911 | ANI PHARMS | Composition for treating Condyloma acuminata |
Oct, 2020
(3 years ago) | |
| US10434059 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(1 year, 5 months ago) | |
| US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(1 year, 2 months from now) | |
| US7858662 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(2 years from now) | |
Veregen is owned by Ani Pharms.
Veregen contains Sinecatechins.
Veregen has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Veregen are:
- US5968973
- US5795911
- US10434059
Veregen was authorised for market use on 31 October, 2006.
Veregen is available in ointment;topical dosage forms.
Veregen can be used as treatment of genital warts.
The generics of Veregen are possible to be released after 02 October, 2026.
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT;TOPICAL
More Information on Dosage
VEREGEN family patents
